Abstract
Evolocumab significantly reduced low-density lipoprotein (LDL) cholesterol. Patients were started on background lipid-lowering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period of 4 to 12 weeks.
Among the 901 patients included in the primary analysis, the overall least-squares mean (+/- SE) reduction in LDL cholesterol from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0 +/- 2.1% (P<0.001). The mean reduction was 55.7 +/- 4.2% among patients who underwent background therapy with diet alone, 61.6 +/- 2.6% among those who received 10 mg of atorvastatin, 56.8 +/- 5.3% among those who received 80 mg of atorvastatin, and 48.5 +/- 5.2% among those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all comparisons).At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks.